Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Net Margin (2020 - 2025)

Journey Medical (DERM) has disclosed Net Margin for 6 consecutive years, with 13.6% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin rose 274.0% year-over-year to 13.6%, compared with a TTM value of 14.53% through Sep 2025, up 3341.0%, and an annual FY2024 reading of 26.14%, down 1968.0% over the prior year.
  • Net Margin was 13.6% for Q3 2025 at Journey Medical, up from 24.89% in the prior quarter.
  • Across five years, Net Margin topped out at 50.28% in Q4 2023 and bottomed at 124.17% in Q4 2021.
  • Average Net Margin over 5 years is 33.71%, with a median of 31.0% recorded in 2025.
  • Peak annual rise in Net Margin hit 11712bps in 2023, while the deepest fall reached -7708bps in 2023.
  • Year by year, Net Margin stood at 124.17% in 2021, then skyrocketed by 46bps to 66.84% in 2022, then surged by 175bps to 50.28% in 2023, then tumbled by -77bps to 11.62% in 2024, then crashed by -217bps to 13.6% in 2025.
  • Business Quant data shows Net Margin for DERM at 13.6% in Q3 2025, 24.89% in Q2 2025, and 31.0% in Q1 2025.